In addition, a research indicated that thalidomide reduces vascular endothelial growth factor (VEGF) and interleukin (IL)-6 expression in the tumor microenvironment accounts, as well as attenuates Hh signaling activity in advanced prostate cancers [14]. Here, VEGFA is linked to prostate cancer.